DNY59
- The U.S. government projects Leqembi, the newly approved Alzheimer’s therapy from Biogen (NASDAQ:BIIB), will cost $3.5B across the entire Medicare program in 2025, far higher than its co-developer Eisai (OTCPK:ESAIY) (OTCPK:ESALF) estimates, Stat News reported.
- A document from a February call at the Centers for Medicare & Medicaid Services (CMS) indicated that the per member spending on the anti-amyloid therapy will reach $4.67 per month in 2025, up from $1.67 in 2024.
- That implies about $550M for traditional Medicare and $3.5B for the entire Medicare program in 2025, Stat reported.
- In March, Eisai (OTCPK:ESAIY) set its 2026 sales forecast for the drug at $1.9B (¥290B). After winning full FDA approval in July 2023, the Japanese drugmaker launched Leqembi with its U.S. partner Biogen (BIIB) at an annual list price of $26.5K per patient before discounts or rebates.
More on Biogen, Eisai, etc.
- Biogen Inc. (BIIB) Stifel 2024 Virtual CNS Days (Transcript)
- Eisai: All About Lenvima And Leqembi
- Biogen Inc. (BIIB) TD Cowen 44th Annual Health Care Conference - (Transcript)
- GLP-1s benefit Parkinson’s: Barclays sees implications across biopharma
- Eisai submits sBLA for monthly maintenance dose of Alzheimer's drug Leqembi